Skip to main content
Premium Trial:

Request an Annual Quote

Start-Up Protein Chip Firm Protometrix Names First President

NEW YORK, Feb. 21 - Start-up protein-chip company Protometrix has hired its first president, GenomeWeb learned on Thursday.


Holly Kleinert will take the helm of the Guilford, Conn.-based firm on March 1. She takes over from Mike Sherman, who helped get the company off the ground last August and is its current acting president.


"We wanted to find somebody with big pharma experience since they're our most-likely clients, and we wanted someone who can relate best to their needs," Sherman said in an interview.

Kleinert, who currently oversees the cardiovascular program at Searle, will run a 15-person company at a time when proteomics, and more specifically protein arrays, are gaining momentum in the genomics marketplace.


Protometrix has three facets: It performs high-throughput protein cloning, expression, and purification; it develops microarrays based on those clones; and it creates software that integrates and keeps track of data.


The technology around which the company is built recently squeezed 5,800 purified yeast proteins--nearly the organism's entire proteome--onto a single microarray. Called a 'nanowell' protein chip by the Yale scientist who co-developed it, the process took four years to create and is not yet on the market.

Making the array, which contains some 13,000 spots, is not automated and thus takes roughly 6 weeks, said Michael Snyder, the Yale scientist and faculty member who helped develop it. He added that Protometrix now can produce the array in about 10 days, and Sherman said that the company may soon be able to crank out a complete yeast protein chip "in a couple of days." Doing one in an afternoon is not far off, he added.


Protometrix is also trying to parlay its yeast technology into human protein technology. Studies researching this are ongoing, Sherman said.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.